ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Ovarian Cancer Targeted Therapy Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-10O17236
Home | Market Reports | Health| Health Conditions| Cancer
Global Ovarian Cancer Targeted Therapy Drugs Market Research Report 2024
BUY CHAPTERS

Global Ovarian Cancer Targeted Therapy Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-10O17236
Report
November 2025
Pages:127
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck KGaA
GlaxoSmithKline PLC
Johnson & Johnson Services Inc.
F. Hoffmann-La Roche AG
Boehringer Ingelheim International GmbH
AbbVie
Astrazeneca plc
Pfizer Inc
Clovis Oncology
Amgen Inc
Johnson & Johnson Services Inc.

Ovarian Cancer Targeted Therapy Drugs Market Size

The global Ovarian Cancer Targeted Therapy Drugs market is projected to grow from US$ 1823 million in 2024 to US$ 3222 million by 2031, at a CAGR of 8.6% (2025-2031), driven by critical product segments and diverse end‑use applications.

Ovarian Cancer Targeted Therapy Drugs Market

Ovarian Cancer Targeted Therapy Drugs Market

Ovarian cancer is the most common cause of mortality for women with gynecological cancers Additionally, it ranks as the seventh most common cause of mortality for females overall. The majority of instances are discovered when the disease has already progressed, which leads to poor outcomes. The cancer cells can be marked with a specific targeted therapy, making it simpler for the immune system to recognize and eliminate them. In addition, some targeted therapies can help in enhancing the immune system so that it fights cancer effectively which further boost the market growth.
Asia-Pacific expected to grow at the highest rate during the ovarian cancer drugs market forecast. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in personalized medicine expenditure and adoption of high-tech processing to improve the production of ovarian cancer drugs, drive the growth of the market. In addition, high population base, presence of unmet medical needs, and increase in disposable incomes of people in the region further boost the market growth. Moreover, rise in medical tourism and developing healthcare infrastructure make Asia-Pacific a lucrative market for ovarian cancer drugs.Furthermore, increase in technological innovations in drug discovery, surge in funding provided by the government and private organizations, presence of large number of healthcare reforms, and increase in aging population of woman drive the growth of the market. Moreover, increase in demand for advanced healthcare services in emerging economies such as India and China are the major factors that drive the growth of the Asia-Pacific market. Asia-Pacific offers profitable opportunities for key players operating in the ovarian cancer drugs market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rising disposable incomes, as well as well-established presence of domestic companies in the region. In addition, rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Ovarian Cancer Targeted Therapy Drugs market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Ovarian Cancer Targeted Therapy Drugs Market Report

Report Metric Details
Report Name Ovarian Cancer Targeted Therapy Drugs Market
Accounted market size in 2024 US$ 1823 million
Forecasted market size in 2031 US$ 3222 million
CAGR 8.6%
Base Year 2024
Forecasted years 2025 - 2031
Segment by Type
  • PARP Inhibitors
  • Angiogenesis Inhibitors
  • Others
Segment by Application
  • Hospital Pharmacy
  • Drug Stores and Retail Pharmacy
  • Online Providers
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Merck KGaA, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Abbvie Inc, AstraZeneca, Pfizer, Inc, Clovis Oncology, Amgen Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Ovarian Cancer Targeted Therapy Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is Ovarian Cancer Targeted Therapy Drugs Market growing?

Ans: The Ovarian Cancer Targeted Therapy Drugs Market witnessing a CAGR of 8.6% during the forecast period 2025-2031.

What is the Ovarian Cancer Targeted Therapy Drugs Market size in 2031?

Ans: The Ovarian Cancer Targeted Therapy Drugs Market size in 2031 will be US$ 3222 million.

Who are the main players in the Ovarian Cancer Targeted Therapy Drugs Market report?

Ans: The main players in the Ovarian Cancer Targeted Therapy Drugs Market are Merck KGaA, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Abbvie Inc, AstraZeneca, Pfizer, Inc, Clovis Oncology, Amgen Inc.

What are the Application segmentation covered in the Ovarian Cancer Targeted Therapy Drugs Market report?

Ans: The Applications covered in the Ovarian Cancer Targeted Therapy Drugs Market report are Hospital Pharmacy, Drug Stores and Retail Pharmacy, Online Providers

What are the Type segmentation covered in the Ovarian Cancer Targeted Therapy Drugs Market report?

Ans: The Types covered in the Ovarian Cancer Targeted Therapy Drugs Market report are PARP Inhibitors, Angiogenesis Inhibitors, Others

1 Study Coverage
1.1 Introduction to Ovarian Cancer Targeted Therapy Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Ovarian Cancer Targeted Therapy Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 PARP Inhibitors
1.2.3 Angiogenesis Inhibitors
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Ovarian Cancer Targeted Therapy Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacy
1.3.3 Drug Stores and Retail Pharmacy
1.3.4 Online Providers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Ovarian Cancer Targeted Therapy Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Ovarian Cancer Targeted Therapy Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Ovarian Cancer Targeted Therapy Drugs Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Ovarian Cancer Targeted Therapy Drugs Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 PARP Inhibitors Market Size by Players
3.3.2 Angiogenesis Inhibitors Market Size by Players
3.3.3 Others Market Size by Players
3.4 Global Ovarian Cancer Targeted Therapy Drugs Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Ovarian Cancer Targeted Therapy Drugs Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Ovarian Cancer Targeted Therapy Drugs Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Ovarian Cancer Targeted Therapy Drugs Market Size by Type (2020-2031)
6.4 North America Ovarian Cancer Targeted Therapy Drugs Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Ovarian Cancer Targeted Therapy Drugs Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Ovarian Cancer Targeted Therapy Drugs Market Size by Type (2020-2031)
7.4 Europe Ovarian Cancer Targeted Therapy Drugs Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Ovarian Cancer Targeted Therapy Drugs Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size by Type (2020-2031)
8.4 Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Ovarian Cancer Targeted Therapy Drugs Market Size by Type (2020-2031)
9.4 Central and South America Ovarian Cancer Targeted Therapy Drugs Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Ovarian Cancer Targeted Therapy Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Ovarian Cancer Targeted Therapy Drugs Market Size by Type (2020-2031)
10.4 Middle East and Africa Ovarian Cancer Targeted Therapy Drugs Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Ovarian Cancer Targeted Therapy Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Merck KGaA
11.1.1 Merck KGaA Corporation Information
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.1.4 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.1.5 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Revenue by Product in 2024
11.1.6 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Revenue by Application in 2024
11.1.7 Merck KGaA Ovarian Cancer Targeted Therapy Drugs Revenue by Geographic Area in 2024
11.1.8 Merck KGaA Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
11.1.9 Merck KGaA Recent Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Corporation Information
11.2.2 GlaxoSmithKline plc Business Overview
11.2.3 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.2.4 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.2.5 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Revenue by Product in 2024
11.2.6 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Revenue by Application in 2024
11.2.7 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs Revenue by Geographic Area in 2024
11.2.8 GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
11.2.9 GlaxoSmithKline plc Recent Developments
11.3 Johnson & Johnson Services, Inc
11.3.1 Johnson & Johnson Services, Inc Corporation Information
11.3.2 Johnson & Johnson Services, Inc Business Overview
11.3.3 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.3.4 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.3.5 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Revenue by Product in 2024
11.3.6 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Revenue by Application in 2024
11.3.7 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs Revenue by Geographic Area in 2024
11.3.8 Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
11.3.9 Johnson & Johnson Services, Inc Recent Developments
11.4 F. Hoffmann-La Roche AG
11.4.1 F. Hoffmann-La Roche AG Corporation Information
11.4.2 F. Hoffmann-La Roche AG Business Overview
11.4.3 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.4.4 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.4.5 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Revenue by Product in 2024
11.4.6 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Revenue by Application in 2024
11.4.7 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs Revenue by Geographic Area in 2024
11.4.8 F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
11.4.9 F. Hoffmann-La Roche AG Recent Developments
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Corporation Information
11.5.2 Boehringer Ingelheim International GmbH Business Overview
11.5.3 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.5.4 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.5.5 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Revenue by Product in 2024
11.5.6 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Revenue by Application in 2024
11.5.7 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs Revenue by Geographic Area in 2024
11.5.8 Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
11.5.9 Boehringer Ingelheim International GmbH Recent Developments
11.6 Abbvie Inc
11.6.1 Abbvie Inc Corporation Information
11.6.2 Abbvie Inc Business Overview
11.6.3 Abbvie Inc Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.6.4 Abbvie Inc Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.6.5 Abbvie Inc Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Corporation Information
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.7.4 AstraZeneca Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.7.5 AstraZeneca Recent Developments
11.8 Pfizer, Inc
11.8.1 Pfizer, Inc Corporation Information
11.8.2 Pfizer, Inc Business Overview
11.8.3 Pfizer, Inc Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.8.4 Pfizer, Inc Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.8.5 Pfizer, Inc Recent Developments
11.9 Clovis Oncology
11.9.1 Clovis Oncology Corporation Information
11.9.2 Clovis Oncology Business Overview
11.9.3 Clovis Oncology Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.9.4 Clovis Oncology Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.9.5 Clovis Oncology Recent Developments
11.10 Amgen Inc.
11.10.1 Amgen Inc. Corporation Information
11.10.2 Amgen Inc. Business Overview
11.10.3 Amgen Inc. Ovarian Cancer Targeted Therapy Drugs Product Features and Attributes
11.10.4 Amgen Inc. Ovarian Cancer Targeted Therapy Drugs Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Ovarian Cancer Targeted Therapy DrugsIndustry Chain Analysis
12.1 Ovarian Cancer Targeted Therapy Drugs Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Ovarian Cancer Targeted Therapy Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Ovarian Cancer Targeted Therapy Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Merck KGaA
GlaxoSmithKline PLC
Johnson & Johnson Services Inc.
F. Hoffmann-La Roche AG
Boehringer Ingelheim International GmbH
AbbVie
Astrazeneca plc
Pfizer Inc
Clovis Oncology
Amgen Inc
Johnson & Johnson Services Inc.
List of Tables
 Table 1. Global Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Ovarian Cancer Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Ovarian Cancer Targeted Therapy Drugs by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ovarian Cancer Targeted Therapy Drugs as of 2024)
 Table 11. Global Ovarian Cancer Targeted Therapy Drugs Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Ovarian Cancer Targeted Therapy Drugs Companies Headquarters
 Table 13. Global Ovarian Cancer Targeted Therapy Drugs Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Ovarian Cancer Targeted Therapy Drugs Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Ovarian Cancer Targeted Therapy Drugs High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Ovarian Cancer Targeted Therapy Drugs Growth Accelerators and Market Barriers
 Table 25. North America Ovarian Cancer Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Ovarian Cancer Targeted Therapy Drugs Growth Accelerators and Market Barriers
 Table 27. Europe Ovarian Cancer Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Ovarian Cancer Targeted Therapy Drugs Investment Opportunities and Key Challenges
 Table 31. Central and South America Ovarian Cancer Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Ovarian Cancer Targeted Therapy Drugs Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Ovarian Cancer Targeted Therapy Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Merck KGaA Corporation Information
 Table 35. Merck KGaA Description and Major Businesses
 Table 36. Merck KGaA Product Features and Attributes
 Table 37. Merck KGaA Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Merck KGaA Revenue Proportion by Product in 2024
 Table 39. Merck KGaA Revenue Proportion by Application in 2024
 Table 40. Merck KGaA Revenue Proportion by Geographic Area in 2024
 Table 41. Merck KGaA Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
 Table 42. Merck KGaA Recent Developments
 Table 43. GlaxoSmithKline plc Corporation Information
 Table 44. GlaxoSmithKline plc Description and Major Businesses
 Table 45. GlaxoSmithKline plc Product Features and Attributes
 Table 46. GlaxoSmithKline plc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. GlaxoSmithKline plc Revenue Proportion by Product in 2024
 Table 48. GlaxoSmithKline plc Revenue Proportion by Application in 2024
 Table 49. GlaxoSmithKline plc Revenue Proportion by Geographic Area in 2024
 Table 50. GlaxoSmithKline plc Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
 Table 51. GlaxoSmithKline plc Recent Developments
 Table 52. Johnson & Johnson Services, Inc Corporation Information
 Table 53. Johnson & Johnson Services, Inc Description and Major Businesses
 Table 54. Johnson & Johnson Services, Inc Product Features and Attributes
 Table 55. Johnson & Johnson Services, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Johnson & Johnson Services, Inc Revenue Proportion by Product in 2024
 Table 57. Johnson & Johnson Services, Inc Revenue Proportion by Application in 2024
 Table 58. Johnson & Johnson Services, Inc Revenue Proportion by Geographic Area in 2024
 Table 59. Johnson & Johnson Services, Inc Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
 Table 60. Johnson & Johnson Services, Inc Recent Developments
 Table 61. F. Hoffmann-La Roche AG Corporation Information
 Table 62. F. Hoffmann-La Roche AG Description and Major Businesses
 Table 63. F. Hoffmann-La Roche AG Product Features and Attributes
 Table 64. F. Hoffmann-La Roche AG Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. F. Hoffmann-La Roche AG Revenue Proportion by Product in 2024
 Table 66. F. Hoffmann-La Roche AG Revenue Proportion by Application in 2024
 Table 67. F. Hoffmann-La Roche AG Revenue Proportion by Geographic Area in 2024
 Table 68. F. Hoffmann-La Roche AG Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
 Table 69. F. Hoffmann-La Roche AG Recent Developments
 Table 70. Boehringer Ingelheim International GmbH Corporation Information
 Table 71. Boehringer Ingelheim International GmbH Description and Major Businesses
 Table 72. Boehringer Ingelheim International GmbH Product Features and Attributes
 Table 73. Boehringer Ingelheim International GmbH Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Boehringer Ingelheim International GmbH Revenue Proportion by Product in 2024
 Table 75. Boehringer Ingelheim International GmbH Revenue Proportion by Application in 2024
 Table 76. Boehringer Ingelheim International GmbH Revenue Proportion by Geographic Area in 2024
 Table 77. Boehringer Ingelheim International GmbH Ovarian Cancer Targeted Therapy Drugs SWOT Analysis
 Table 78. Boehringer Ingelheim International GmbH Recent Developments
 Table 79. Abbvie Inc Corporation Information
 Table 80. Abbvie Inc Description and Major Businesses
 Table 81. Abbvie Inc Product Features and Attributes
 Table 82. Abbvie Inc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Abbvie Inc Recent Developments
 Table 84. AstraZeneca Corporation Information
 Table 85. AstraZeneca Description and Major Businesses
 Table 86. AstraZeneca Product Features and Attributes
 Table 87. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. AstraZeneca Recent Developments
 Table 89. Pfizer, Inc Corporation Information
 Table 90. Pfizer, Inc Description and Major Businesses
 Table 91. Pfizer, Inc Product Features and Attributes
 Table 92. Pfizer, Inc Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Pfizer, Inc Recent Developments
 Table 94. Clovis Oncology Corporation Information
 Table 95. Clovis Oncology Description and Major Businesses
 Table 96. Clovis Oncology Product Features and Attributes
 Table 97. Clovis Oncology Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Clovis Oncology Recent Developments
 Table 99. Amgen Inc. Corporation Information
 Table 100. Amgen Inc. Description and Major Businesses
 Table 101. Amgen Inc. Product Features and Attributes
 Table 102. Amgen Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Amgen Inc. Recent Developments
 Table 104. Raw Materials Key Suppliers
 Table 105. Distributors List
 Table 106. Market Trends and Market Evolution
 Table 107. Market Drivers and Opportunities
 Table 108. Market Challenges, Risks, and Restraints
 Table 109. Research Programs/Design for This Report
 Table 110. Key Data Information from Secondary Sources
 Table 111. Key Data Information from Primary Sources


List of Figures
 Figure 1. Ovarian Cancer Targeted Therapy Drugs Product Picture
 Figure 2. Global Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. PARP Inhibitors Product Picture
 Figure 4. Angiogenesis Inhibitors Product Picture
 Figure 5. Others Product Picture
 Figure 6. Global Ovarian Cancer Targeted Therapy Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Hospital Pharmacy
 Figure 8. Drug Stores and Retail Pharmacy
 Figure 9. Online Providers
 Figure 10. Ovarian Cancer Targeted Therapy Drugs Report Years Considered
 Figure 11. Global Ovarian Cancer Targeted Therapy Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Ovarian Cancer Targeted Therapy Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Region (2020-2031)
 Figure 15. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share Ranking (2024)
 Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 17. PARP Inhibitors Revenue Market Share by Player in 2024
 Figure 18. Angiogenesis Inhibitors Revenue Market Share by Player in 2024
 Figure 19. Others Revenue Market Share by Player in 2024
 Figure 20. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Type (2020-2031)
 Figure 21. Global Ovarian Cancer Targeted Therapy Drugs Revenue Market Share by Application (2020-2031)
 Figure 22. North America Ovarian Cancer Targeted Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 23. North America Top 5 Players Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) in 2024
 Figure 24. North America Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Type (2020 - 2031)
 Figure 25. North America Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 26. US Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 27. Canada Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 28. Mexico Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 29. Europe Ovarian Cancer Targeted Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. Europe Top 5 Players Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) in 2024
 Figure 31. Europe Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 32. Europe Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 33. Germany Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 34. France Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 35. U.K. Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 36. Italy Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 37. Russia Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 38. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Top 8 Players Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) in 2024
 Figure 40. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Asia-Pacific Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Indonesia Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 43. Japan Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 44. South Korea Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 45. Australia Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 46. India Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 47. Indonesia Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 48. Vietnam Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 49. Malaysia Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 50. Philippines Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 51. Singapore Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2031) & (US$ Million)
 Figure 52. Central and South America Ovarian Cancer Targeted Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 53. Central and South America Top 5 Players Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) in 2024
 Figure 54. Central and South America Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 55. Central and South America Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Brazil Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 57. Argentina Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 58. Middle East and Africa Ovarian Cancer Targeted Therapy Drugs Revenue YoY (2020-2031) & (US$ Million)
 Figure 59. Middle East and Africa Top 5 Players Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) in 2024
 Figure 60. South America Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Type (2020-2031)
 Figure 61. Middle East and Africa Ovarian Cancer Targeted Therapy Drugs Revenue (US$ Million) by Application (2020-2031)
 Figure 62. GCC Countries Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 63. Israel Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 64. Egypt Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 65. South Africa Ovarian Cancer Targeted Therapy Drugs Revenue (2020-2025) & (US$ Million)
 Figure 66. Ovarian Cancer Targeted Therapy Drugs Industry Chain Mapping
 Figure 67. Channels of Distribution (Direct Vs Distribution)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Therapies and Diagnostics for Ovarian Cancer Market Insights Forecast to 2030
Global Ovarian Cancer Drugs Market Insights Forecast to 2030
Global Ovarian Cancer Diagnostics and Therapeutics Market Insights Forecast to 2030
Global Cancer Targeted Drug Market Research Report 2025
Global Oncology Targeted Therapy Market Research Report 2025
Global Ovarian Cancer Market Research Report 2024
Global Cancer Targeted Small Molecule Therapy Market Research Report 2025
Global Epithelial Ovarian Cancer Treatment Market Research Report 2024
Global Targeted Small Molecule Therapy Market Research Report 2025
Global Targeted Small Molecule Drug Market Research Report 2025
Global Targeted Cancer Therapy Market Research Report 2024
Global Targeted Therapy for Breast Cancer Market Research Report 2025
Global Gynecological Cancers Therapeutics Market Insights Forecast to 2030
Global Targeted Antitumor Drugs Market Research Report 2025
Global Targeted Oncology Drugs Market Research Report 2024
Gynaecological Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Small Molecule Targeted Cancer Therapy Market Research Report 2025
Global Fallopian Tube Cancer Therapeutics Market Insights Forecast to 2030
Global Targeted Radiotherapy Drug Market Research Report 2024
Global Injectable Targeted Therapy Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions